Compare KeyCorp (KEY) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KeyCorp vs Natera Inc. Common Stock — how do they compare? KeyCorp trades at $19.83 (market cap $21.25B), while Natera Inc. Common Stock trades at $394 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 2.7× KeyCorp's market cap, and KeyCorp pays a 4.12% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold KeyCorp for 66 Days and Natera Inc. Common Stock for 0 Days on average.
| KEY | NTRA | |
|---|---|---|
Market Cap | $21.25B | $57.03B |
Volume | 17,676,934 | 1,131,157 |
Sector | Financials | Health |
52-Week High | $23.99 | $425.64 |
52-Week Low | $16.78 | $179.42 |
Typical Hold Time | 66 Days | 0 Days |
Enterprise Value | $34.43B | $56.18B |
Dividend Yield | 4.12% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KeyCorp (KEY) trades at $19.79, down 1.49% on the day, with a bearish technical signal but strong fundamentals including a P/E of 11.64 and net income margin of 26.72%. Recent quarterly earnings have consistently beaten expectations, and the company maintains a $0.21 dividend. Analyst consensus is bullish with a $25.00 price target, though recent news highlights competitive dividend pressures.
The outlook for KEY is positive based on earnings momentum and valuation, but risks include interest rate sensitivity and frozen dividends. Upside potential exists if loan growth and fee income continue to drive revenue, yet investor sentiment is cautious amid technical weakness and macroeconomic uncertainty.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About KeyCorp
With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
